Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2021Coronary Artery Disease

The prognostic value of neutrophil-to-lymphocyte ratio across all stages of coronary artery disease

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Despite advances in prevention and therapy, additional cardiovascular risk reduction is needed, highlighting inflammation as a potential therapeutic target.

Does the neutrophil-to-lymphocyte ratio predict prognosis in patients across all stages of coronary artery disease?

Population

Patients across all stages of coronary artery disease, including atherosclerosis, chronic coronary syndrome…

Design

Review

Discussion

Loading...

Member takes

Implication

May refine CAD risk stratification; leaves open whether NLR-guided therapy improves outcomes.

Structured PICO

Does the neutrophil-to-lymphocyte ratio predict prognosis in patients across all stages of coronary artery disease?

P
Population
Patients across all stages of coronary artery disease, including atherosclerosis, chronic coronary syndrome (CCS), acute coronary syndrome (ACS), and heart failure
I
Intervention
Neutrophil-to-lymphocyte ratio (NLR) measurement
O
Outcome
Prognosis, including major adverse cardiac events (MACEs), mortality, and pathological cardiac remodeling

The neutrophil-to-lymphocyte ratio is a promising inflammatory biomarker that predicts poor prognosis and adverse outcomes across the entire spectrum of coronary artery disease.

Cite This Study

A 2021 study studied this question.

synapsesocial.com/papers/6a7d38d21e40f4486896593bhttps://doi.org/10.1097/mca.0000000000001040

Topics

Coronary artery disease
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biomarker assessment for early infarct size estimation in ST-elevation myocardial infarction2019 · 30 citations
  2. 2Neutrophil-to-Lymphocyte Ratio Predicts Outcomes in Patients Implanted with Left Ventricular Assist Devices2015 · 20 citations
  3. 3T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients2015 · 158 citations
  4. 4In-Stent Restenosis in the Drug-Eluting Stent Era2010 · 812 citations
  5. 5Trends in Cause of Death After Percutaneous Coronary Intervention2014 · 187 citations